Changes in Hong Kong stocks | Baiosetu-B (02315) rose more than 5%. The company recently officially entered the Hong Kong Stock Connect list. The agency said that Qianmuwan Resistance has begun to be realized

The Zhitong Finance App learned that Biosetu-B (02315) rose by more than 5%. As of press release, it had risen 4.94% to HK$36.08, with a turnover of HK$27.5841 million.

According to the news, the Shanghai Stock Exchange and the Shenzhen Stock Exchange recently announced that the Baiosetu will be transferred to the Hong Kong Stock Connect stock list with effect from December 24, 2025. This move marks another important milestone after the company established an “A+H” dual capital market platform. Since then, its Hong Kong stock channel has been fully opened to mainland investors.

A previous research report by Huafu Securities pointed out that the company's thousands of vaccines have begun to be implemented, and antibody licensing has driven an explosion in performance. Considering the high growth and high barriers of the company's business, the basic market for pre-clinical animal and pharmacological efficacy evaluation is stable, and the antibody development business has gradually entered a performance delivery period. Combined with potential new drug pipelines, it has the potential to be “buy” for the first time.